Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
May 20, 2004
SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide
David A Barda, Zhao-Qing Wang, Thomas C Britton, et al.
Plos One
|
December 27, 2007
An animal model of emotional blunting in schizophrenia
Charmaine Y Pietersen, Fokko J Bosker, Janine Doorduin, et al.
Psychopharmacology
|
February 18, 2005
Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)
Michael P Johnson, David Barda, Thomas C Britton, et al.
Physical Therapy
|
October 17, 2015
Workforce Projections 2010-2020: Annual Supply and Demand Forecasting Models for Physical Therapists Across the United States
Michel D Landry, Laurita M Hack, Elizabeth Coulson, et al.
British Journal of Pharmacology
|
February 9, 2017
Broad spectrum efficacy with LY2969822, an oral prodrug of metabotropic glutamate 2/3 receptor agonist LY2934747, in rodent pain models
Michael P Johnson, Mark A Muhlhauser, Eric S Nisenbaum, et al.
Cephalalgia : an International Journal of Headache
|
August 21, 2025
Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine
Michael P Johnson, Judith Krikke-Workel, Chetan N Patel, et al.
Neuroscience Letters
|
September 17, 2002
Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagonists
Ann E Kingston, Kelly Griffey, Michael P Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 13, 2018
In Vitro Pharmacological Characterization and In Vivo Validation of LSN3172176 a Novel M1 Selective Muscarinic Receptor Agonist Tracer Molecule for Positron Emission Tomography
Adrian J Mogg, Thomas Eessalu, Megan Johnson, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 3, 2016
Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache
Maria-Jesus Blanco, Dana R Benesh, James A Knobelsdorf, et al.
Science Translational Medicine
|
May 15, 2020
PET ligands [<sup>18</sup>F]LSN3316612 and [<sup>11</sup>C]LSN3316612 quantify <i>O</i>-linked-β-<i>N</i>-acetyl-glucosamine hydrolase in the brain
Shuiyu Lu, Mohammad B Haskali, Kevin M Ruley, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Bioorganic & Medicinal Chemistry Letters
|
May 20, 2004
SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide
David A Barda, Zhao-Qing Wang, Thomas C Britton, et al.
Plos One
|
December 27, 2007
An animal model of emotional blunting in schizophrenia
Charmaine Y Pietersen, Fokko J Bosker, Janine Doorduin, et al.
Psychopharmacology
|
February 18, 2005
Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)
Michael P Johnson, David Barda, Thomas C Britton, et al.
Physical Therapy
|
October 17, 2015
Workforce Projections 2010-2020: Annual Supply and Demand Forecasting Models for Physical Therapists Across the United States
Michel D Landry, Laurita M Hack, Elizabeth Coulson, et al.
British Journal of Pharmacology
|
February 9, 2017
Broad spectrum efficacy with LY2969822, an oral prodrug of metabotropic glutamate 2/3 receptor agonist LY2934747, in rodent pain models
Michael P Johnson, Mark A Muhlhauser, Eric S Nisenbaum, et al.
Cephalalgia : an International Journal of Headache
|
August 21, 2025
Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine
Michael P Johnson, Judith Krikke-Workel, Chetan N Patel, et al.
Neuroscience Letters
|
September 17, 2002
Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagonists
Ann E Kingston, Kelly Griffey, Michael P Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 13, 2018
In Vitro Pharmacological Characterization and In Vivo Validation of LSN3172176 a Novel M1 Selective Muscarinic Receptor Agonist Tracer Molecule for Positron Emission Tomography
Adrian J Mogg, Thomas Eessalu, Megan Johnson, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 3, 2016
Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache
Maria-Jesus Blanco, Dana R Benesh, James A Knobelsdorf, et al.
Science Translational Medicine
|
May 15, 2020
PET ligands [<sup>18</sup>F]LSN3316612 and [<sup>11</sup>C]LSN3316612 quantify <i>O</i>-linked-β-<i>N</i>-acetyl-glucosamine hydrolase in the brain
Shuiyu Lu, Mohammad B Haskali, Kevin M Ruley, et al.
Page
of 7